Agreement with Production Partner for HAMLET Peptide
Hamlet Pharma reaches the important goal of establishing large-scale production of the drug candidate for Phase II clinical trials. For this purpose, Hamlet Pharma now signs a production and development agreement with PolyPeptide Laboratories Holding (PPL) AB. PPL is part of the PolyPeptide Group - one of the largest contract manufacturers of peptides and peptide-related molecules in the world. PolyPeptide is represented globally with manufacturing facilities in the US, Europe and India that have been approved by the FDA. The implementation of Phase II clinical studies requires large